Satsuma Pharmaceuticals, Inc(NASDAQ:STSA) 
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in AS...
Website: http://www.satsumarx.com
Founded: 2016
IPO Price: $15 (Sep 13, 2019)
Full Time Employees: 17
CEO: John A. Kollins
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2022-12-08
P
O 0.81
H 0.94
L 0.81
C 0.86
V 275,683
10EMA 0.86
20EMA 0.86
60EMA 0.86
120EMA 0.86
250EMA 0.86